Intercept Pharmaceuticals, Inc.

NasdaqGS:ICPT Voorraadrapport

Marktkapitalisatie: US$794.7m

Intercept Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Intercept Pharmaceuticals is Jerry Durso, benoemd in Jan2021, heeft een ambtstermijn van 2.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.46M, bestaande uit 16% salaris en 84% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.12% van de aandelen van het bedrijf, ter waarde $ 984.47K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.7 jaar en 8.7 jaar.

Belangrijke informatie

Jerry Durso

Algemeen directeur

US$4.5m

Totale compensatie

Percentage CEO-salaris16.0%
Dienstverband CEO2.8yrs
Eigendom CEO0.1%
Management gemiddelde ambtstermijn2.7yrs
Gemiddelde ambtstermijn bestuur8.7yrs

Recente managementupdates

Recent updates

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Jun 08
Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Apr 11
Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Dec 20
Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Sep 20

Intercept cuts debt further with deal to exchange convertible notes

Sep 02

Intercept reduces debt with repurchases of $327.9M convertible notes

Aug 19

Intercept Pharmaceuticals: Too Risky To Buy At This Stage

Aug 13

Intercept Pharma Q2 2022 Earnings Preview

Aug 02

Intercept to resubmit for FDA approval of NASH candidate after new analysis

Jul 07

Intercept: Increase Of Ocaliva Sales And A Few Catalysts

May 23

Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

May 10
Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH

Mar 05

Intercept names Andrew Saik as chief financial officer

Jun 07

Intercept Pharmaceuticals slides as FDA restricts Ocaliva use

May 26

Analyse CEO-vergoeding

Hoe is Jerry Durso's beloning veranderd ten opzichte van Intercept Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2023n/an/a

-US$57m

Jun 30 2023n/an/a

-US$159m

Mar 31 2023n/an/a

-US$173m

Dec 31 2022US$4mUS$715k

-US$175m

Sep 30 2022n/an/a

-US$202m

Jun 30 2022n/an/a

-US$115m

Mar 31 2022n/an/a

-US$120m

Dec 31 2021US$8mUS$691k

-US$136m

Sep 30 2021n/an/a

-US$144m

Jun 30 2021n/an/a

-US$193m

Mar 31 2021n/an/a

-US$231m

Dec 31 2020US$4mUS$600k

-US$273m

Sep 30 2020n/an/a

-US$321m

Jun 30 2020n/an/a

-US$339m

Mar 31 2020n/an/a

-US$347m

Dec 31 2019US$4mUS$573k

-US$345m

Sep 30 2019n/an/a

-US$335m

Jun 30 2019n/an/a

-US$314m

Mar 31 2019n/an/a

-US$318m

Dec 31 2018US$3mUS$541k

-US$309m

Sep 30 2018n/an/a

-US$333m

Jun 30 2018n/an/a

-US$341m

Mar 31 2018n/an/a

-US$352m

Dec 31 2017US$4mUS$441k

-US$360m

Compensatie versus markt: De totale vergoeding ($USD 4.46M ) Jerry } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.15M ).

Compensatie versus inkomsten: De vergoeding van Jerry is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jerry Durso (55 yo)

2.8yrs

Tenure

US$4,455,463

Compensatie

Mr. Jerome B. Durso, also known as Jerry, has been President and Chief Executive Officer of Intercept Pharmaceuticals, Inc. since January 1, 2021 and serves as its Director since May 27, 2021. Mr. Durso se...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Jerome Durso
President2.8yrsUS$4.46m0.12%
$ 984.5k
Andrew Saik
Chief Financial Officer2.4yrsUS$1.39m0.055%
$ 437.4k
Jared Freedberg
General Counsel2.8yrsUS$1.31m0.13%
$ 1.1m
Linda Richardson
Executive VP & Chief Commercial Officer2.8yrsUS$1.34m0.040%
$ 317.4k
M. Berrey
President of Research & Development and Chief Medical Officer2.4yrsUS$1.61m0.068%
$ 538.6k
Rocco Venezia
Chief Accounting Officer & Treasurer2.7yrsUS$856.23k0.061%
$ 483.6k
Nareg Sagherian
Executive Director of Global Investor Relations1.9yrsgeen gegevensgeen gegevens
David Ford
Chief Human Resources Officer6.5yrsUS$1.91m0.036%
$ 285.7k
Mark Pruzanski
Founder2.8yrsUS$6.43m1.48%
$ 11.8m
Paul Nitschmann
Senior Vice President of Regulatory Affairsno datageen gegevensgeen gegevens
Kathleen Munster
Chief Quality Officer & SVP of Technical Operationsless than a yeargeen gegevensgeen gegevens
Michael Blash
Senior Vice President of Corporate Affairsless than a yeargeen gegevensgeen gegevens

2.7yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ICPT wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Jerome Durso
President2.5yrsUS$4.46m0.12%
$ 984.5k
Mark Pruzanski
Founder21.8yrsUS$6.43m1.48%
$ 11.8m
Daniel Bradbury
Independent Chairman7.3yrsUS$327.39k0.056%
$ 447.4k
Glenn Sblendorio
Independent Director9.8yrsUS$332.39k0.056%
$ 445.5k
Luca Benatti
Independent Director9.3yrsUS$327.39k0.061%
$ 484.3k
Srinivas Akkaraju
Independent Director11.1yrsUS$317.39k0.091%
$ 719.8k
Gino Santini
Lead Independent Director8yrsUS$337.39k0.057%
$ 449.2k
Alan Hofmann
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Scott L. Friedman
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Massimo Pinzani
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Aldo Roda
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Keith Gottesdiener
Independent Director7.3yrsUS$322.39k0.059%
$ 469.7k

8.7yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ICPT wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.7 jaar).